1st Quarter - Report
ARENTFOX SCHIFF LLP for ALLERGAN PLC
Firm
Client
Income
$120,000
Expenses
—
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 672 (Prescription Drug Abuse Prevention and Treatment Act of 2013), all provisions Abuse deterrent formulations
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY DEMSKE | — |
| PHILIP ENGLISH | — |
Trade (domestic/foreign) TRD
Trans-Pacific Partnership (TPP) intellectual property protection and policy
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILIP ENGLISH | — |
| JAMES HUNTER | — |
Copyright/Patent/Trademark CPT
S. 1720 (Patent Transparency and Improvements Act of 2013), entire bill S. 1013 (Patent Abuse Reduction Act of 2013)(Section 5), all provisions relating to fee shifting
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY DEMSKE | — |
| PHILIP ENGLISH | — |
Medicare/Medicaid MMM
Medicare reimbursements for oncology drugs
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY DEMSKE | — |
| PHILIP ENGLISH | — |
| JAMES HUNTER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.